Update on the epidemiology, diagnosis, and treatment of posttraumatic stress disorder by Zohar, Joseph et al.
osttraumatic stress disorder (PTSD) is a
maladaptive response to a traumatic event, which is
currently underdiagnosed and undertreated. It is
probable that several myths that surround PTSD,
for example, that it is almost solely related to com-
bat situations and that it is a “normal” response to
a traumatic situation, have contributed to poor
recognition of this disorder. The misconception
regarding combat and PTSD is reflected in the his-
tory of the names given to the disorder—“shell
shock,” “soldier’s heart,” “combat neurosis,” and
“operational fatigue.” However, in the late 1980s, it
was realized that PTSD is related to all types of
traumatic events, including rape, physical attack,
severe automobile accidents, and natural or human-
made disasters. Consequently, the terms for the dis-
order were changed to “traumatic neurosis” and
later to “posttraumatic stress disorder,” and the
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Posttraumatic stress disorder (PTSD) is a maladaptive, pathological response to a traumatic event, which is cur-
rently underdiagnosed and undertreated. This results in part from a lack of awareness regarding the prevalence
of the disorder. It has been estimated that at least one third of the general population will be exposed to severe
trauma throughout their lifetime, out of which approximately 10% to 20% develop PTSD. A prevalence of 3%
to 6% of PTSD in the general population, found in several studies, corresponds well with these figures. Both the
type of trauma and the personal characteristics of the individual involved are associated with the probability
of developing PTSD. The Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV) gives four diag-
nostic criteria: (i) exposure and emotional response to a traumatic event; (ii) reexperiencing; (iii) avoidance; and
(iv) increased physiological arousal, along with severe impairment in occupational, social, and interpersonal func-
tioning. The rate of comorbidity with other mental disorders is high, particularly for major depression, anxiety
disorders, and substance abuse. Different types of psychological intervention, including cognitive-behavioral
therapy and a host of pharmacological interventions, have been tried. Selective serotonin reuptake inhibitors
(SSRIs) are currently the most widely researched agents with consistent, though modest, therapeutic effects.
Other compounds, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) have also
been found to be effective, although their use is limited due to side effects. PTSD is a psychobiological phe-
nomenon in response to psychological trauma, which represents maladaptive neurobiological dysregulation and
psychological dysfunction, and awaits further recognition and research.
PInterpretation of symptoms, which we would now con-
sider indicating a diagnosis of PTSD, as a “normal
response” to traumatic events has further impeded
progress in the field.Based on extensive epidemiological
studies, it is becoming increasingly clear that the vast
majority of individuals who are exposed to a traumatic
event will later adapt and continue with their lives.Only
a small percentage,which partially depends on the sever-
ity and the duration of the trauma and partially on addi-
tional factors,will develop a pathological fixation on the
traumatic event,ie,PTSD.
According to the 4th edition of the Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM-IV),there are
three subtypes of PTSD: (i) acute; (ii) chronic; and (iii)
with delayed onset.These subtypes are defined according
to when the symptoms appear in relation to the key trau-
matic event and their duration, although all subsets
require a minimum duration of 1 month.Symptom dura-
tion of less than 3 months that appear within 6 months of
the trauma is diagnosed as acute-form PTSD. Chronic
PTSD corresponds to duration of symptoms of more
than 3 months,and delayed-onset PTSD corresponds to
an onset of at least 6 months after initial traumatic expo-
sure (and may begin up to several decades later).
Epidemiology
It has been estimated that at least one third of the pop-
ulation will be exposed to a severe trauma during their
lifetime.
3,4 Since 10% to 20% of individuals exposed to
severe trauma will develop PTSD,
5 according to this fig-
ure, the prevalence of PTSD in the general population
will range from 3% to 6%.This estimation has been con-
firmed in several studies carried out in the United
States,
4,6,7 but not in others.
8,9 
The type and magnitude of the trauma on the one hand,
and the characteristics of the individual on the other,
are all factors associated with the probability of devel-
oping PTSD. Personal characteristics that have been
associated with higher risk of developing PTSD include
high neuroticism scores,
6 preexisting depression and anx-
iety
8 (especially social phobia), early history of adver-
sity, and exposure to traumatic events in childhood
(childhood separation from parents, childhood abuse,
sexual assault,and parental divorce in early childhood).
6
It also seems that, at least in relation to assaultive vio-
lence, the female gender is associated with higher risk.
8
Other predictors include socioeconomic status:individ-
uals from lower socioeconomic levels may be more
prone to develop PTSD.
6
The association between the type of trauma and the dif-
ferential risk of developing PTSD has been investigated
in a number of epidemiological studies. Kessler et al,
6
in data deriving from 5877 persons 15 to 54 years of age
from the larger National Comorbidity Survey (NCS) of
8098,found that PTSD was associated with 65% of rape
cases in males (although the number of times this par-
ticular event occurred was very small) and with 49.5% of
rape cases in women, with 38.8% of combat-related
events, and with 21.3% of women who were faced with
criminal assault.Breslau et al
4 also report that the high-
est risks of developing PTSD following civilian trau-
matic events were associated with rape (49.0%±12.2%),
followed by being badly beaten up (31.9%±8.6%),and
other kinds of sexual assault (23.7%±10.8%).
Definition and diagnosis of PTSD 
The diagnostic criteria for PTSD are listed in both the
DSM-IV and the International Classification of Dis-
eases, 10th revision (ICD-10). The criteria are essen-
tially the same,with the exception that no time require-
ment is stipulated in the ICD-10.As the authors believe
that the element of time is critical in this disorder, the
DSM-IV seems to be a more appropriate diagnostic
system, and, indeed, has been applied much more
widely in studies.
There are four main diagnostic criteria,or characteristic
features, of PTSD. These are: exposure to a traumatic
event,reexperiencing,avoidance,and increased arousal.
According to the DSM-IV,only extreme traumatic stres-
sors,in contrast with general stressful experiences,have
been linked etiologically to PTSD.Such traumatic events
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Pharmacological aspects
Selected abbreviations and acronyms
CBT cognitive-behavioral treatment
5-HT 5-hydroxytryptamine (serotonin)
MAOI monoamine oxidase inhibitor
NCS National Comorbidity Survey
PTSD posttraumatic stress disorder
SSRI serotonin selective reuptake inhibitor
TCA tricyclic antidepressant39
are defined as situations in which “the person experi-
enced, witnessed, or was confronted with an event or
events that involved actual or threatened death or seri-
ous injury, or a threat to the physical integrity of self or
others …”(DSM-IV,p 427).As per this definition,very
severe humiliation,or any other type of disappointment
or intense stress, does not fulfill the criteria for a trau-
matic event. On the other hand, it has been recognized
in the DSM-IV that an individual does not need to be
exposed to a trauma that is “outside the range of usual
human experience,” as previously defined by DSM-III.
Moreover,the DSM-IV has added an important element
to the diagnosis: the emotional response, which is char-
acterized as “intense fear,helplessness,or horror”;DSM-
IV,p 428),and hence,the diagnostic criteria in DSM-IV
is more stringent in this regard.
The second feature of PTSD is reexperiencing (Criterion
B).The PTSD patient is emotionally stuck in the trau-
matic event, even many years after it has occurred, and
constantly reexperiencing it in various ways:flashbacks;
stressful recollections;recurrent,distressing dreams;act-
ing or feeling as if the traumatic event were reoccurring
or experiencing intense psychological distress or physi-
ological reactivity following exposure to internal or
external cues that symbolize or resemble the event.
An additional maladaptive mechanism used by patients
diagnosed with other anxiety disorders,including patients
with PTSD,is avoidance.Avoidance is listed as Criterion C
in the DSM-IV’s definition of PTSD.Patients with PTSD
attempt to avoid any stimuli associated even in a periph-
eral way with the trauma, including smells, feelings,
thoughts,activities,places,or people.This avoidance often
expresses itself as “emotional anesthesia,”ie,“markedly
diminished interest or participation in significant activi-
ties,” “feeling of detachment,” a “restricted range of
affect,” and a “sense of a foreshortened future.” Some-
times amnestic or dissociative symptoms (which may also
be interpreted as avoidance) appear in response to the
extreme reexperiencing, and are thought of as another
maladaptive mechanism that originally evolves to buffer
the individual from painful recollections.
The fourth feature of PTSD (Criterion D) is increased
arousal. Patients are constantly “on alert,” have diffi-
culty in falling or staying asleep, suffer from irritability
or outbursts of anger,have difficulty concentrating,and
experience hypervigilance and exaggerated startle
response. For many of the patients and their families,
this group of symptoms is particularly difficult as the
families need to maintain a very calm environment while
the patients are concerned about losing control.
An additional criterion relates to the functional impair-
ment of the symptoms,described as causing severe impair-
ment in social,occupational,and family areas of life.
Comorbidity with other mental disorders is prevalent
in PTSD.A recent epidemiologic survey indicated that
approximately 80% of PTSD patients meet criteria for
at least one other psychiatric diagnosis.
3,10The most com-
mon disorders experienced concurrently with PTSD
found in the US National Comorbidity study are major
depression (48.5 in women and 47.9 in men),other anx-
iety disorders (more than one third), and substance
abuse (found in one third of women and half of all
men).
6 Depression seems to be a common disorder
found in comorbidity with PTSD as evidenced by addi-
tional studies of different populations.
11,12 Since symp-
toms such as guilt, ruminations, decreased concentra-
tion, anxiety, and outbursts of anger are parts of other,
more familiar disorders, the diagnosis of PTSD may be
overlooked. Many times such patients may be misdiag-
nosed with depression, sleep disturbance, personality
disorder, substance abuse, malingering, or even schizo-
phrenia.
4,5
Two studies of psychotic female inpatients demonstrate
this point.These studies indicate that patients with a his-
tory of childhood sexual abuse were more likely to have
intrusive, avoidant/numbing, and hyperarousal symp-
toms than their nonabused counterparts; a full 66% of
these women met the diagnosis for PTSD,but had never
been diagnosed.
13,14
It has further been suggested that the high levels of
comorbidity may point to the possibility of several dif-
ferent subgroups of PTSD.
15-17 An example of such a
grouping is development of psychological or behavioral
problems before, concurrent with, or after exposure to
the traumatic stressor.
16 An alternative approach sug-
gests that the picture may be more complex, that asso-
ciated psychiatric disorders are not purely comorbid,
but “interwoven with the PTSD.”
17
Treatment approaches
Treatment can either be applied to “seal over” the dis-
tress of the patient or do exactly the opposite, to
“uncover the pain,”which can then facilitate resolution
of the traumatic experience in conjunction with psycho-
logically oriented therapy.
18 Accordingly, it has been
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(SSRIs) and tricyclic antidepressants (TCAs) are use-
ful in helping the patient to “put their fears away,”while
cognitive-behavioral treatment (CBT) helps patients via
stress inoculation, training, and exposure
19,20 to better
cope with the traumatic event.
Psychological treatment
The effect of different courses of psychological treat-
ment are only beginning to be systematically reviewed.
A combined approach to treatment is generally consid-
ered to be beneficial, especially in the acute stages.
21
CBTs are the most developed, and have been most rig-
orously tested;they include a variety of treatments such
as exposure procedures, cognitive restructuring proce-
dures,and anxiety management programs (for a review,
see Foa and Meadows
20). Further methodologically
sound research is needed to follow up on the encourag-
ing preliminary research.
Psychopharmacological treatment
The aim of pharmacotherapy is to reduce symptoms of
intrusion and generalization of the trauma, lower the
degree of avoidance and numbing behavior, reduce
hyperarousal,and decrease impulsivity and dissociative
symptoms.
22
While attempting pharmacological intervention for
patients with PTSD, careful listing of the main symp-
toms is advisable, and the therapeutic effect of medica-
tions should be evaluated according to the specific
changes in those symptoms.In addition,patients should
be made aware that it may take as long as 10 weeks, or
even longer,to attain the maximal beneficial response.
Emerging data indicate that antidepressant medications
may have more prominent roles in the treatment of this
disorder, namely, selective serotonin reuptake inhibitors
(SSRIs),tricyclic antidepressants (TCAs),and monoamine
oxidase inhibitors (MAOIs).
Serotonin selective reuptake inhibitors (SSRIs)  
SSRIs are currently the most widely investigated agents,
and have been studied in several large, multinational,
double-blind,placebo-controlled studies.Based on stud-
ies with sertraline and fluoxetine,and on additional pos-
itive open studies with other SSRIs,namely fluvoxamine
and paroxetine, it is becoming increasingly clear that
SSRIs are effective in the treatment of PTSD. More-
over, the symptomatic changes are related to the core
symptoms of PTSD and not merely to unspecified
changes.The doses used in these studies were 40 mg for
fluoxetine,100 to 150 mg for sertraline,150 to 300 mg for
fluvoxamine,and a mean dose of 40 mg for paroxetine.
Tricyclic antidepressants (TCAs) 
Two double-blind studies with amitriptyline and
imipramine showed these drugs to be superior to
placebo in PTSD by a difference of 35% in number of
improved patients.
23-25 Doses used were 150 to 250 mg
of amitriptyline and a mean dose of 225 mg for
imipramine. However, as PTSD patients have low tol-
erance for side effects (related to their hyperarousal
cluster of symptoms),TCAs have not been widely used
in PTSD. It is of interest to note that there appears to
be an inverse relationship between the intensity of
exposure to trauma and the success of treatment with
TCAs.
Monoamine oxidase inhibitors (MAOIs)
In a study that compared imipramine with phenelzine,at
a mean dose of 68 mg, and placebo,
23 a better rate of
improvement was demonstrated in the phenelzine group
(68%) than in the placebo group (28%). Moreover,
phenelzine-treated patients showed better treatment
retention than those treated with imipramine (7.4 weeks
vs 5.6 weeks for imipramine and 5.5 weeks for placebo)
and also improved more on globally assessed symptoms
(phenelzine: 44%; imipramine: 25%; placebo: 28%).
23
However, it is important to note the attendant risks,
namely, hypertensive crisis, if the dietary restrictions
(low tyramine diet) associated with this medication are
not kept. In a disorder where impulsiveness and the
abuse of alcohol are often present these risks may be
even higher.
If the patient is not responding, or if the response is
partial, one possibility is to switch from one group of
medication to another, eg, switching from SSRIs to
another group, such as TCAs or MAOIs, or else, to
make a switch within the same group,eg,switching from
one SSRI (or one TCA) to another.
40
Pharmacological aspectsAlthough the available data are very limited, another
alternative may be to switch from SSRIs to nefazodone,
since the side-effect profile of this medication is very
favorable and its mode of action quite different. Nefa-
zodone potently antagonizes 5-HT2 receptors while also
inhibiting both serotonin and norepinephrine reuptake.
The recommended dose for depression is 200 mg twice a
day,which would probably be suitable for PTSD as well,
providing double-blind studies are able to demonstrate
the efficacy in this condition.
Benzodiazepines
Regarding the available evidence on benzodiazepines,
this group of drugs to have limited efficacy in the treat-
ment of PTSD.Braun et al
26 found no significant differ-
ence between alprazolam and placebo in a group of 10
patients who had treatment-resistant illness.
Propranolol has been administered in open studies of
children and adults and was found to improve PTSD
symptoms in most of the studies. The role of propra-
nolol is still unclear and needs to be further examined in
double-blind studies.
Augmentation therapies in PTSD
Although little is known about augmentation strategies
in PTSD, one possible approach to treating an individ-
ual who is partly responsive or nonresponsive to treat-
ment is in accordance with the symptomatic approach,
ie, if the patient is suffering from an outburst of anger,
mood stabilizers such as lithium,carbamezapine,or val-
proic acid might be added.
27,28 If anxiety and irritability
are present, a buspirone augmentation is an option to
be considered.
29
Another possibility for augmentation is for a patient
who is very agitated. In such cases, small doses of
antipsychotics might be administered.The case for the
addition of antipsychotics is even stronger if a concur-
rence of psychosis and PTSD is present. Indeed, there
are several case reports demonstrating the efficacy of
thioridazine, olanzapine, risperidone, and clozapine.
30
Buspirone, a 5-HT1A agonist, and clonidine have been
administered either alone or as augmenting agents in
PTSD.As buspirone may be associated with decrease
of anxiety, it may be administered either as an aug-
menting agent for SSRIs or TCAs, or as a stand-alone
drug (10-20 mg, three times daily).
Clonidine has been reported in open studies to be effec-
tive in ameliorating PTSD symptoms, especially the
depression component.Although it has also been used
as an augmenting agent for imipramine, double-blind
studies are needed in order to substantiate this claim.
There are a number of case reports with antidepres-
sants such as trazodone, venlafaxine, and bupropion,
which in very limited cases under open conditions were
reported to be of benefit in improving PTSD symp-
toms. The doses used were 300 mg for trazodone, 250
mg for venlafaxine, and 300 mg for bupropion.
Duration of treatment
Very little is known regarding maintenance treatment
of the disorder. It seems, though, that there is a spon-
taneous decrease in the symptoms of PTSD in the first
6 months following the trauma,which continues up to 4
or 5 years. From this standpoint, one should take into
account this spontaneous recovery when applying psy-
chopharmacological intervention during the first 5
years after the trauma, ie, a gradual down-titration of
the dose is called for in order to evaluate whether the
medication is really needed.
The same basic rules about discontinuation of medica-
tion in other anxiety disorders apply here as well,
namely, slow and gradual discontinuation, every 6
weeks or so.The down-titration of medication should
be in very small doses.Only if by the end of this period
there is no sign of symptom exacerbation may the
patient proceed to the next titration. In cases of dete-
rioration, a return to the previous dose seems logical,
although evidence to confirm this is lacking.
For patients who have exceeded the 4- to 5-year period,
it seems that long-term administration of medication is
often needed, although there is still the possibility of
spontaneous remission, as long as 10 years following
the trauma.
A special consideration for long-term maintenance
treatment of patients with PTSD is in relation to spe-
cific dates in the year that may be associated with an
exacerbation of PTSD symptoms, such as the anniver-
sary of the trauma,or memorial days for veterans with
PTSD. During these periods, specific close monitor-
ing may be appropriate, with the possible addition of
nonbenzodiazepine hypnotics and anxiolytics,or alter-
natively,preparing the patient by increasing the dose of
medication that was used throughout the year.
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The prevalence of PTSD ranges from 1.5% to 6% in
different studies of different populations. The disorder
has severe consequences on the quality of life, not only
of the individuals afflicted, but also for their families
and significant others. Although it is a prevalent and
severe disorder,PTSD is currently underdiagnosed,and
consequently undertreated.
The diagnostic criteria for PTSD are comprised of four
components: the trauma (including the immediate
emotional response); reexperiencing; avoidance
(including “emotional anesthesia”);and hyperarousal.
In order to identify PTSD patients, specific questions
addressing these points need to be included in every
mental status examination, especially if elements of
depression,anxiety,oubursts of anger,or drug or alco-
hol abuse are present,as they often appear to be seque-
lae of PTSD.
Treatment should take a broad approach, addressing
familial and occupational issues as well.Currently,SSRIs
are emerging as the pharmacological treatment of choice
for this disorder,as demonstrated in large double-blind,
placebo-controlled,multicenter studies.
However, the effect size, though significant, is modest.
Clearly,more research and better therapeutic interven-
tions are called for in this unique disorder, which, as
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Puesta al día en la epidemiología, el
diagnóstico y el tratamiento del
trastorno de estrés postraumático
El trastorno de estrés postraumático (TEPT) es una
respuesta patológica, que traduce una mala adapta-
ción frente a un acontecimiento traumático. Este cua-
dro está actualmente subdiagnosticado y subtratado.
Esto se debe en parte a una falta de conciencia acerca
de la prevalencia de este trastorno.Se ha estimado que
al menos un tercio de la población general estará
expuesta a un trauma severo en algún momento de su
vida, y de ellos aproximadamente un 10% a 20%
desarrollará un TEPT.En diversos estudios en pobla-
ción general se ha encontrado una prevalencia entre
el 3% y el 6% de TEPT, lo que se corresponde bien
con el marco de referencia antes enunciado.Tanto el
tipo de trauma, como las características personales
del individuo afectado se asocian con la probabilidad
de desarrollar un TEPT. El Manual Diagnóstico y
Estadístico de los Trastornos Mentales en su cuarta
edición  (DSM-IV) determina cuatro criterios diag-
nósticos para el TEPT: a) exposición y respuesta
emocional al acontecimiento traumático,b) re-experi-
mentar el acontecimiento, c) conductas de evitación y
d) aumento de la activación fisiológica. Todos estos
criterios se traducen en un severo deterioro del fun-
cionamiento ocupacional, social e interpersonal. La
frecuencia de comorbilidad con otros trastornos men-
tales es alta,especialmente con depresión mayor,tras-
tornos de ansiedad y abuso de sustancias. Se han
ensayado diferentes tipos de intervenciones psicológi-
cas incluyendo terapia cognitivo conductual y varia-
dos tratamientos farmacológicos. Los inhibidores
selectivos de la recaptación de serotonina (ISRS) han
sido los fármacos más ampliamente investigados y se
ha encontrado que sus efectos terapéuticos, aunque
modestos, son consistentes. Otros medicamentos
como los antidepresivos tricíclicos (AT) y los inhibi-
dores de la mono amino oxidasa (IMAO) han
demostrado ser efectivos, pero su uso está limitado
por los efectos secundarios indeseables. El TEPT
constituye un fenómeno psicobiológico, en respuesta
al trauma psicológico, que representa una disregula-
ción neurobiológica de mala adaptación y una dis-
función psicológica que requiere de mayor reconoci-
miento e investigación en el futuro.
Mise au point sur l'épidémiologie, le
diagnostic et le traitement de l’état de
stress post-traumatique
L’état de stress post-traumatique (ESPT) correspond
à une réponse inadaptée et pathologique à un événe-
ment traumatisant. Ce trouble est actuellement sous-
diagnostiqué et sous-traité, en partie en raison d’une
mauvaise appréciation de sa prévalence. On a estimé
qu’au moins le tiers de la population générale sera
exposée à un traumatisme sévère au cours de sa vie et
que 10 à 20% de cette population développera un
ESPT. Plusieurs études ont trouvé une prévalence de
3 à 6% d’ESPT dans la population générale, ce qui
correspond bien à ce schéma.Le type du traumatisme
et les caractéristiques personnelles du sujet impliqué
sont corrélés à la probabilité de développer un ESPT.
La 4e édition du Manuel Diagnostique et Statistique
des Troubles Mentaux (DSM-IV) définit quatre cri-
tères diagnostiques : l’exposition et la réponse émo-
tionnelle à un événement traumatisant ;la réexpérien-
ce ;l’évitement et l’hyperactivité neurovégétative,ainsi
qu’une altération sévère des activités professionnelles,
sociales et interpersonnelles. Le taux de comorbidité
avec d’autres troubles mentaux est élevé,particulière-
ment en ce qui concerne les dépressions majeures,les
troubles anxieux et l’usage de substances toxiques.
Différents types d’aides psychologiques,y compris la
thérapie cognitivo-comportementale et un grand
nombre de traitements médicamenteux ont été essayés.
Les inhibiteurs de la recapture de la sérotonine (IRS)
sont actuellement les médicaments faisant l'objet des
recherches les plus nombreuses, car ils ont des effets
thérapeutiques constants,bien que modestes.D’autres
composés, tels que les antidépresseurs tricycliques et
les inhibiteurs de la monoamine oxydase (IMAO),se
sont aussi montrés actifs,bien que leur utilisation soit
limitée par leurs effets secondaires. L'ESPT, phéno-
mène psychobiologique en réponse à un traumatisme
psychologique qui correspond à une dysrégulation
neurobiologique inadaptée et à un dysfonctionnement
psychologique, nécessite donc de faire l'objet d'une
meilleure identification et d'une recherche accrue.